|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
SundaySerono seeks OK for new form of MS drug Rebif
MORE...REUTERS
Swiss biotech company Serono SA (SEO.VX: Quote, Profile, Research) said on Tuesday it had asked U.S. and European regulators to approve a new and better-tolerated formulation of its Rebif treatment for multiple sclerosis. The company said in a statement that late-stage trials of the new formulation showed a "substantial improvement in overall tolerability," including less incidence of inflammation at the site of injections. Serono said the trials also showed that patients taking the new formulation developed fewer antibodies -- immune system proteins that might attack the medicine -- a favorable finding that typically suggests a drug will work longer.... |